Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript Summary
Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA loss improved by 33% to $8.4 million from a loss of $12.5 million year-over-year.The following is a summary of the Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript:
以下是Butterfly Network, Inc.（BFLY）2024年第三季度業績會成績單：
Financial Performance:
金融業績：
Butterfly Network reported Q3 2024 revenue of $20.6 million, marking a 33% year-over-year increase.
Gross profit increased to $12.2 million, up 30% from the previous year, although gross margin percentage slightly decreased to 59.5%.
Adjusted EBITDA loss improved by 33% to $8.4 million from a loss of $12.5 million year-over-year.
They anticipate Q4 2024 revenue to be in the range of $20 to $22 million with an expected adjusted EBITDA loss of $10 to $12 million.
Butterfly Network報告2024年第三季度營業收入爲2060萬美元，同比增長33%。
毛利潤增至1220萬美元，比上一年增長30%，儘管毛利率百分比略微下降至59.5%。
調整後的EBITDA虧損從上一年的1250萬美元虧損提升33%至840萬美元。
他們預計2024年第四季度營業收入將在20至2200萬美元的區間內，並預計調整後的EBITDA虧損在10至1200萬美元之間。
Business Progress:
業務進展：
Introduced four strategic pillars during an Investor Day including accelerating core business growth, advancing R&D, expanding into new markets, and improving operational efficiency.
Launched iQ3 domestically and internationally, and implemented the ScanLab AI training app.
Established partnerships and expanded into new markets including Indonesia, Netherlands, Belgium, and more.
Announced the formation of Octiv, a subsidiary focused on licensing and commercializing ultrasound technology.
在投資者日介紹了四個戰略支柱，包括加速核心業務增長，推進研發，拓展新市場和提高運營效率。
在國內和國際上推出了iQ3，並實施了ScanLab人工智能培訓應用程序。
建立了夥伴關係並進入印度尼西亞、荷蘭、比利時等新市場。
宣佈成立Octiv，這是專注於許可和商業化超聲波技術的子公司。
Opportunities:
機會：
Expansion into home care services with a pilot for virtual chronic care management services starting in Q4 2024, targeting the Medicare advantage provider segment.
Launched iQ3 internationally, broadening the product's global reach and aiming for revenue growth in 2025 from higher average selling prices and additional probes in distribution.
Developing proprietary Butterfly iQ Station and forthcoming P5 chip technologies for entering ultrasound cart markets.
擴展家庭護理服務，從2024年第四季度開始試點虛擬慢性護理管理服務，目標是醫療優勢提供商領域。
在全球推出了iQ3，擴大了該產品的全球覆蓋範圍，並旨在通過更高的平均銷售價格和分銷中的附加探頭實現在2025年的營業收入增長。
開發了專有的Butterfly iQ Station和即將推出的P5芯片技術，以進入超聲波車市場。
Risks:
風險：
Consumer acceptance and market penetration for new product launches like iQ3 and upcoming technologies could affect future revenue projections.
Dependency on strategic partnerships and international market expansions that involve complex regulatory and market dynamics.
消費者對像iQ3這樣的新產品發佈和即將推出的技術的接受程度以及市場滲透率可能會影響未來營業收入預測。
依賴戰略合作伙伴關係和涉及複雜監管和市場動態的國際市場拓展，可能會對業務的未來發展產生影響。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
